# Effect of Evolocumab on Saphenous Vein Graft Patency Following Coronary Artery Bypass Surgery

> **NCT03900026** · PHASE4 · COMPLETED · sponsor: **Unity Health Toronto** · enrollment: 782 (actual)

## Conditions studied

- Coronary Artery Bypass Graft Surgery
- Atherosclerosis
- Vein Occlusion

## Interventions

- **DRUG:** Evolocumab
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03900026
- **Lead sponsor:** Unity Health Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-05-30
- **Primary completion:** 2025-01-30
- **Final completion:** 2025-01-30
- **Target enrollment:** 782 (ACTUAL)
- **Last updated:** 2025-08-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03900026

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03900026, "Effect of Evolocumab on Saphenous Vein Graft Patency Following Coronary Artery Bypass Surgery". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03900026. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*